Precancer detection

Identify esophageal disease before cancer develops

The groundbreaking EsoGuard DNA test is changing the way esophageal precancer is detected. Now disease can be identified in a simple office-based visit without endoscopy.

What is the EsoGuard test?

The EsoGuard DNA test detects abnormal esophageal cells to identify disease before it progresses. With ~90% sensitivity and ~99% negative predictive value at detecting Barrett's esophagus1,2,3 as well as esophageal adenocarcinoma,1,2 the EsoGuard test allows for detection of these conditions so they can be effectively managed or treated.

Learn More

Clinical need

Esophageal Adenocarcinoma has increased over 500% in the past 4 decades4,5

In the United States, esophageal cancer claims more lives than melanoma skin cancer and cervical cancer combined.

Only about 20% of patients diagnosed with esophageal cancer survive five years after diagnosis. Even early-stage cancer has a 5-year survival of only ~50%.4,5 This makes early detection of the easily treatable precancerous conditional critical for this highly lethal disease.

The science

Early detection powered by Targeted Next Generation Sequencing

The EsoGuard assay uses targeted next generation sequencing (NGS) to examine individual DNA molecules for the presence or absence of cytosine methylation at 31 different genomic locations. EsoGuard assesses the presence of methylation in targeted regions of the Vimentin and CCNA1 genes after the samples have undergone bisulfite conversion—a chemical step which allows characterization of DNA methylation at CpG sites. 

See the Data

Non-Invasive Targeted Cell Collection

EsoCheck with Collect+Protect™ Technology is a quick, non-invasive way for clinicians to collect surface esophageal cells for analysis, without endoscopy. The small EsoCheck capsule, similar in size to a daily vitamin or gel cap, is easy for patients to swallow. 

Learn About Esocheck

Who is at risk?

The risk of esophageal precancer is highest in patients with gastroesophageal reflux disease (GERD), age over 50, male, white race, obesity, smoking, and a family history of esophageal precancer (Barrett's esophagus) or cancer (esophageal adenocarcinoma).6,7 

At least thirty million at-risk individuals with gastroesophageal disease (GERD), also known as chronic heartburn, are recommended for esophageal precancer testing by professional society clinical practice guidelines to prevent highly lethal esophageal cancer. Precancer detection is essential because esophageal cancer survival rates are poor, even when detected at Stage I.

Chronic GERD
Male Sex
White Race
Age Over 50
Family History of Esophageal Precancer or Cancer
Don M.

"If you're seeing symptoms of reflux, a chronic cough, ask your doctor to screen you. Don't take reflux lightly. Reflux can equal Barrett's, can equal esophageal cancer."

Scott S.

"I caught my Barrett's esophagus early enough in the stages that I avoided surgery and they could cure my problem without doing a major surgery. I felt that the EsoGuard test saved my life."

Angela W.

"I was unaware that I had GERD because my symptoms (cough, difficulty swallowing, and hoarseness) were "normal" to me. After receiving the results I was referred to a GI specialist for an upper GI scope and diagnosed with Barrett's esophagus. I was not symptomatic so I am grateful that this test screened for the precancerous condition. Knowledge is power!  I gained valuable information about my health and made lifestyle changes. I will repeat the scope in 2 years to determine if my condition has stabilized or worsened."

Daniel R.

“It was two minutes for the rest of my life, because of the EsoGuard test my disease was caught and treated.”

Brian L.

"I got screened as a baseline check, to see if there are any indicators of a precancer, a cancer...really to be proactive for my own health. Early detection is everything"

Host a #CheckYourFoodTube Esophageal Precancer Testing Event

Firefighters have a 62% increased risk of developing esophageal cancer and 39% increased risk of dying of the disease.8 The EsoGuard DNA test offers early detection for those at increased risk, which is why we partner with fire departments across the country to host convenient group screening events.

Host an Event

Insurance + Billing

Lucid Diagnostics accepts all insurance plans and directly bills medical insurance carriers for the EsoGuard test.

Customer Service

Phone: 1-888-582-4339
Monday-Friday 7:00am to 5:00pm PST

Learn More
1. Moinova, Helen R et al. “Multicenter, prospective trial of non-endoscopic biomarker-driven detection of f Barrett’s Esophagus and Esophageal Adenocarcinoma.” The American Journal of Gastroenterology (2024): 10-14309.
2. Greer, Katarina B et al. “Non-endoscopic screening for Barrett’s Esophagus and Esophageal Adenocarcinoma in at risk veterans.” medRxiv (2024): 2024-03 [Preprint.
3. Shaheen, N., et al., Use of the EsoGuard® Molecular Biomarker Test in Non-Endoscopic Detection of Barrett's Esophagus among High-Risk Individuals in a Screening Population. medRxiv, 2024: p. 2024.06.24.24309401.
4. Hang, Thuy-Van P et al. “The Epidemiology of Esophageal Adenocarcinoma in the United States: Presidential Poster Award: 333.” American Journal of Gastroenterology 113 (2018): S185-S186.
5. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
6. Shaheen, Nicholas J et al. “Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline.” The American journal of gastroenterology vol. 117,4 (2022):559-587.
7. Muthusamy, V Raman et al. “AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 20,12 (2022): 2696-2706.e
8. IAFF date 1.1.2002 to 3.31.2017—NIOSH Research.